Please login to the form below

Not currently logged in
Email:
Password:

ALS

This page shows the latest ALS news and features for those working in and with pharma, biotech and healthcare.

SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director

SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director

Dr Chin has been responsible over the last five years for overseeing the non-clinical development of numerous drug candidates in clinical trials for amyotrophic lateral sclerosis (ALS), spinal muscular atrophy

Latest news

  • Biogen’s Aduhelm unlikely to get approval in Europe Biogen’s Aduhelm unlikely to get approval in Europe

    The news saw the company’s share price drop by 4% in addition to a previous 4% drop the day before after the announcement that its top R&D leader Al

  • Biogen's ALS drug tofersen misses phase 3 endpoint Biogen's ALS drug tofersen misses phase 3 endpoint

    ALS). ALS is a progressive, fatal neurodegenerative disease with an average survival of 3-5 years and SOD1-ALS is a rare, genetic form that accounts for 2% of the estimated ... ALS community, and we welcome this important research advancement in this

  • AZ buys Caelum Biosciences for $500m AZ buys Caelum Biosciences for $500m

    $350m. CAEL-101 is a potential first-in-class monoclonal antibody for the treatment of light chain (AL) amyloidosis. ... Standard treatment for AL amyloidosis is chemotherapy combined with thalidomide and/or steroids, which is effective but can kill the

  • GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

    amyotrophic lateral sclerosis (ALS) in the second half of 2021. ... approved treatments, as well as explore the ability to help patients with other neurodegenerative diseases, such as ALS, Parkinson’s and Alzheimer’s,” he added.

  • Q&A: Amar Urhekar Q&A: Amar Urhekar

    We worked together at McCann in Japan. Just before his 30th birthday, he was diagnosed with ALS. ... He set up the END ALS Association and even wrote a book about it with the aid of eye-tracking software as he was no longer able to type.

More from news
Approximately 13 fully matching, plus 109 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 51 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...